# Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

> **NCT03601611** · NA · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumor
- Colitis
- Arthritis

## Interventions

- **DRUG:** Tocilizumab (RoACTEMRA®)

## Key facts

- **NCT ID:** NCT03601611
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2020-01-28
- **Final completion:** 2020-01-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601611, "Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03601611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*